Retinal vein occlusion (RVO) is an important cause of visual loss among older adults throughout the world . RVO is the second most common cause of vision loss from retinal vascular disease, following diabetic retinopathy . Despite many proposed interventions, there are no treatments proven to reopen occluded retinal veins. Current treatment is directed at secondary complications of RVO that affect vision, including macular edema, retinal neovascularization, and anterior segment neovascularization. Effective treatment for macular capillary nonperfusion, a fourth cause of visual loss in RVO, is not available.
Treatment modalities, including medical therapies, laser photocoagulation, and other surgical therapies, will be discussed here. Epidemiology, pathophysiology, clinical manifestations, and diagnosis of RVO are discussed separately. (See "Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis".)
OVERVIEW OF TREATMENT
There are two major anatomic types of retinal vein occlusion: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). BRVO occurs when a vein in the distal retinal venous system is occluded, leading to hemorrhage along the distribution of a small vessel of the retina. CRVO occurs due to thrombus within the central retinal vein at the level of the lamina cribrosa of the optic nerve, leading to involvement of the entire retina. Less commonly, hemiretinal vein occlusion may occur when there is blockage of a vein draining the superior or inferior hemiretina. (See "Retinal vein occlusion: Epidemiology, clinical manifestations, and diagnosis", section on 'Classification'.)
Treatment for patients with retinal vein occlusion (RVO) is directed at eliminating macular edema, retinal neovascularization, and anterior segment neovascularization.
Macular edema — Pharmacologic treatment with intravitreal anti-VEGF agents is currently first-line therapy for macular edema [3-8]. Intravitreal glucocorticoid therapy is considered a distant alternative . In patients with BRVO, Grid laser photocoagulation therapy is another distant alternative for treatment , but has limited or no benefit in patients with CRVO. There is no established role for prophylactic therapy for macular edema with either anti-VEGF therapy or laser therapy.